Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

AIDS-associated Kaposi's sarcoma.

J O Kahn1, D W Northfelt, S A Miles

  • 1University of California, San Francisco.

AIDS Clinical Review
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Persistently Higher Ratio of Gallbladder Cancer Incidence in Native American People than in Non-Hispanic Whites: Selected United States Regions, 1962-2021.

Journal of racial and ethnic health disparities·2026
Same author

N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Low-level laser therapy reduces time to ambulation in dogs after hemilaminectomy: a preliminary study.

The Journal of small animal practice·2012
Same author

N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2009
Same author

A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer.

British journal of cancer·2003
Same author

Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposure.

The Journal of infectious diseases·2001
Same journal

Human immunodeficiency virus and hepatitis B and C coinfection: pathogenic interactions, natural history, and therapy.

AIDS clinical review·2000
Same journal

Rationale for immune-based therapies for human immunodeficiency virus type 1 infection.

AIDS clinical review·2000
Same journal

Drug interactions of antiretroviral agents.

AIDS clinical review·2000
Same journal

Salvage therapy for patients failing their current antiretroviral regimen.

AIDS clinical review·2000
Same journal

Reconstitution of immunity against opportunistic infections in the era of potent antiretroviral therapy.

AIDS clinical review·2000
Same journal

Can immune responses to human immunodeficiency virus be preserved, enhanced, or restored?

AIDS clinical review·2000
See all related articles

Treatment for AIDS-Kaposi

Area of Science:

  • Oncology
  • Immunology
  • Infectious Diseases

Background:

  • AIDS-Kaposi's Sarcoma (AIDS-KS) management depends on immune suppression levels.
  • CD4+ T lymphocyte counts guide therapeutic decisions.

Purpose of the Study:

  • To outline treatment strategies for AIDS-KS based on immune status.
  • To emphasize palliative care goals for AIDS-KS management.

Main Methods:

  • Treatment selection stratified by CD4+ T lymphocyte counts ( >500/mm3, 200-500/mm3, <200/mm3).
  • Consideration of local therapy, recombinant interferon, systemic chemotherapy, PCP prophylaxis, and antiretroviral therapy.
  • Focus on palliative interventions for functional and cosmetic issues.

Main Results:

Related Experiment Videos

  • Patients with CD4+ >500/mm3 generally require local therapy.
  • Patients with CD4+ 200-500/mm3 may benefit from recombinant interferon, potentially combined with zidovudine.
  • Patients with CD4+ <200/mm3 need PCP prophylaxis, possibly chemotherapy, and continued antiretroviral therapy.

Conclusions:

  • AIDS-KS treatment is not curative; managing underlying immune deficiency is crucial.
  • Therapeutic goals are palliative, aiming to alleviate symptoms like edema, pain, and organ dysfunction.
  • A tailored approach based on immune status ensures rational and effective AIDS-KS management.